• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation (Amendment)

    2/9/24 8:40:49 AM ET
    $IART
    Medical/Dental Instruments
    Health Care
    Get the next $IART alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 7 )*

                

    INTEGRA LIFESCIENCES HOLDINGS CORPORATION


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    457985208


    (CUSIP Number)

    December 29, 2023


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 457985208

    1. NAMES OF REPORTING PERSONS

    Wellington Management Group LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Massachusetts

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 3,106,087
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 3,349,368
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,349,368
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.28%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. 457985208

    1. NAMES OF REPORTING PERSONS

    Wellington Group Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 3,106,087
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 3,349,368
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,349,368
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.28%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. 457985208

    1. NAMES OF REPORTING PERSONS

    Wellington Investment Advisors Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 3,106,087
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 3,349,368
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,349,368
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.28%
    12. TYPE OF REPORTING PERSON

    HC

    Item 1.
    (a) Name of Issuer
    INTEGRA LIFESCIENCES HOLDINGS CORPORATION
    (b) Address of Issuer's Principal Executive Offices
    1100 Campus Road
    Princeton, NJ 08540
    Item 2.
    (a) Name of Person Filing
    Wellington Management Group LLP
    Wellington Group Holdings LLP
    Wellington Investment Advisors Holdings LLP
    (b) Address of Principal Business Office or, if None, Residence
    c/o Wellington Management Company LLP
    280 Congress Street
    Boston, MA 02210
    (c) Citizenship
    Wellington Management Group LLP - Massachusetts
    Wellington Group Holdings LLP - Delaware
    Wellington Investment Advisors Holdings LLP - Delaware
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    457985208
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [ ] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [X] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    See the responses to Item 9 on the attached cover pages.
    (b) Percent of Class:
    See the responses to Item 11 on the attached cover pages.
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 0
    (ii) shared power to vote or to direct the vote See the responses to Item 6 on the attached cover pages.
    (iii) sole power to dispose or to direct the disposition of 0
    (iv) shared power to dispose or to direct the disposition of See the responses to Item 8 on the attached cover pages.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Exhibit A directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows:

    Not Applicable.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    See attached Exhibit A.
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.
    Item 9. Notice of Dissolution of Group.

    Not Applicable.
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2024

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2024

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2024


    Exhibit A

    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.

    Wellington Group Holdings LLP – HC
    Wellington Investment Advisors LLP – HC
    Wellington Management Global Holdings, Ltd. - HC

    One or more of the following investment advisers (the “Wellington Investment Advisers”):

    Wellington Management Company LLP – IA
    Wellington Management Canada LLC – IA
    Wellington Management Singapore Pte Ltd – IA
    Wellington Management Hong Kong Ltd – IA
    Wellington Management International Ltd – IA
    Wellington Management Japan Pte Ltd – IA
    Wellington Management Australia Pty Ltd - IA

    The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.


    EXHIBIT B

    JOINT FILING AGREEMENT

    The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of INTEGRA LIFESCIENCES HOLDINGS CORPORATION is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate. It is understood and agreed that the joint filing of the Schedule 13G shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.


    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2024

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2024

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2024

    Get the next $IART alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IART

    DatePrice TargetRatingAnalyst
    3/31/2025Hold → Buy
    Argus
    12/2/2024$25.00 → $20.00Underweight
    Morgan Stanley
    10/7/2024Sell → Neutral
    BTIG Research
    7/30/2024$22.00Neutral → Sell
    BTIG Research
    7/30/2024$30.00 → $23.00Neutral → Sell
    Citigroup
    5/7/2024Outperform → Perform
    Oppenheimer
    5/7/2024$45.00 → $25.00Overweight → Equal Weight
    Wells Fargo
    4/3/2024$38.00Sell → Neutral
    Citigroup
    More analyst ratings

    $IART
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Integra LifeSciences Holdings Corporation

      SCHEDULE 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      5/9/25 2:16:33 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Integra LifeSciences Holdings Corporation

      10-Q - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

      5/5/25 4:07:05 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

      5/5/25 6:45:23 AM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

      SC 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      11/12/24 5:20:30 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

      SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      11/12/24 12:54:20 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

      SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      8/12/24 10:06:35 AM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Legal Officer & Sec Schwartz Eric covered exercise/tax liability with 2,718 shares, decreasing direct ownership by 5% to 56,020 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      3/13/25 4:30:51 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • EVP & CHIEF FINANCIAL OFFICER Knight Lea Daniels covered exercise/tax liability with 1,655 shares and was granted 20,859 shares, increasing direct ownership by 46% to 61,139 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      3/13/25 4:30:10 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • SVP, Fin & Princ Acct Officer Mosebrook Jeffrey covered exercise/tax liability with 443 shares and was granted 5,514 shares, increasing direct ownership by 14% to 40,882 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      3/13/25 4:28:33 PM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Integra LifeSciences Reports First Quarter 2025 Financial Results

      PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55 in the prior year.Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact

      5/5/25 6:30:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025

      PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conf

      4/18/25 4:30:00 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

      PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and Lea Knight, chief financial officer will present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 17, 2025 at 10:00am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at https://investor.integralife.com/events-and-presentations. About Integra LifeSciencesAt Integra LifeSciences, we are driven by our purpose of restoring patients' lives. We innovate treatment pathways to advance pati

      3/13/25 5:00:00 PM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Leadership Updates

    Live Leadership Updates

    See more

    $IART
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $IART
    Financials

    Live finance-specific insights

    See more

    $IART
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jan De Witte joins GHO Capital as Operating Partner

      Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

      2/11/25 4:30:00 AM ET
      $IART
      $RMD
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer

      PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that its board of directors has appointed Mojdeh Poul as the new president and chief executive officer, effective January 6, 2025. Ms. Poul will also join the Integra board when she assumes the role. She will succeed Jan De Witte, who will remain president and CEO until January 6, 2025. Stuart Essig will remain executive chairman of Integra for a limited period of time before returning to his prior role as non-executive chairman. "The board and I are thrilled to welcome Mojdeh as Integra's next president and CEO," sa

      11/4/24 6:00:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

      Brings proven leadership and successful track record to Halda as the company enters the next stage of growth as clinical-stage company Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced that it has appointed Christian Schade as President and Chief Executive Officer and a member of the Board of Directors. Chris brings more than 20 years of public and private pharmaceutical and biotechnology industry experience, including building, financing and leading biotechnology companies through the clinical stages of pipeline development and formation of value-creating de

      10/1/24 8:30:00 AM ET
      $APRE
      $IART
      $OMGA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Essig Stuart bought $1,499,979 worth of shares (52,641 units at $28.49), increasing direct ownership by 12% to 487,922 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      5/24/24 4:08:19 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Hill Barbara B bought $995,816 worth of shares (36,350 units at $27.40) (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      5/22/24 4:09:18 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences Reports First Quarter 2025 Financial Results

      PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55 in the prior year.Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact

      5/5/25 6:30:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025

      PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conf

      4/18/25 4:30:00 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance

      PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Reported revenues were $442.6 million, representing an increase of 11.5% on a reported basis and an increase of 3.5% on an organic basis compared to the fourth quarter 2023. GAAP earnings per diluted share were $0.25, compared to $0.25 in the fourth quarter 2023. Adjusted earnings per diluted share were $0.97, compared to $0.89 in the fourth quarter 2023. Full-Year 2024 Reported revenues were $1,610.5 million, representing an increase of 4.5% on a reported basis and

      2/25/25 6:00:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra upgraded by Argus

      Argus upgraded Integra from Hold to Buy

      3/31/25 8:28:08 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on Integra with a new price target

      Morgan Stanley initiated coverage of Integra with a rating of Underweight and set a new price target of $20.00 from $25.00 previously

      12/2/24 8:17:21 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra upgraded by BTIG Research

      BTIG Research upgraded Integra from Sell to Neutral

      10/7/24 7:56:40 AM ET
      $IART
      Medical/Dental Instruments
      Health Care